Canakinumab (an anti IL-1β monoclonal antibody) was related to a dose-dependent reduction in heart failure hospitalizations and a composite of hospitalizations and HF-related mortality in a sub-analysis of the CANTOS trial [49] but there was no distinction between HFrEF and HFpEF in that study. Here, IL1B is linked to heart failure.